SS Innovations International, Inc. (NASDAQ: SSII) has announced significant growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of the system also rose 42% to 238 units, up from 168, according to the company’s latest update. This expansion highlights the increasing global demand for robotic-assisted surgery, particularly in markets where access to such technology has traditionally been limited.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments underscore the company’s strategy to make robotic surgery more accessible and affordable across diverse healthcare systems.
In addition to its general surgery applications, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31. Notably, a telesurgery was performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system’s efficiency and high-throughput capabilities. Such achievements are critical as they demonstrate the platform’s reliability and potential to address surgical backlogs in high-volume settings.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal for the company’s expansion into developed markets, where regulatory approval is a prerequisite for commercialization. Success in these regions could significantly broaden the company’s addressable market and accelerate revenue growth.
For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The implications of this announcement are substantial for the medical device industry and investors. The rapid adoption of the SSi Mantra, particularly in emerging markets, signals a shift toward more cost-effective robotic surgery solutions. As healthcare systems worldwide seek to improve surgical outcomes while managing costs, SS Innovations’ progress could position it as a key player in the global robotic surgery market. The upcoming regulatory decisions in the U.S. and Europe will be critical in determining the company’s ability to compete with established players and to sustain its growth trajectory.
